Trial Profile
A Phase 2a, Randomized, Double Blind, Placebo-controlled, Parallel Group Study Investigating The Dose-response Of Pf-00489791 On Acute Hemodynamics In Subjects With Idiopathic And Familial Pulmonary Arterial Hypertension
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs PF 489791 (Primary) ; Sildenafil
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors Pfizer
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 19 Jun 2014 New trial record